000108502 001__ 108502 000108502 005__ 20230519145353.0 000108502 0247_ $$2doi$$a10.1080/03007995.2020.1847718 000108502 0248_ $$2sideral$$a121669 000108502 037__ $$aART-2021-121669 000108502 041__ $$aeng 000108502 100__ $$aMcMahon, S.B. 000108502 245__ $$aThe burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty 000108502 260__ $$c2021 000108502 5060_ $$aAccess copy available to the general public$$fUnrestricted 000108502 5203_ $$aThis document presents the conclusions of a detailed discussion on the role of topical NSAIDs during a round table Global Pain Faculty meeting held in Amsterdam in 2019 and subsequent discussions online. The aim of this evidence-based document is to describe the impact of musculoskeletal pain both in terms of the large numbers of sufferers and its economic impact. The document considers the place of topical therapies alongside other pharmacological and non-pharmacological treatments and presents the evidence for the benefits and harms of topical NSAIDS including indicators of efficacy for three main topical NSAIDs– diclofenac, ibuprofen and ketoprofen–based on almost 15, 000 participants in randomized controlled trials for acute and chronic musculoskeletal pain. These topical NSAIDs have the largest body of evidence. For acute pain, numbers needed to treat to achieve at least 50% reduction in pain are as follows with 95% confidence intervals in brackets: Diclofenac emulgel 1.8(1.5–2.1) (5170 participants), Ibuprofen gel 2.7 (1.7–4.2) (436 participants), Ketoprofen gel 2.2 (1.7–2.8) (683 participants). For chronic pain, the NNTs are Diclofenac any formulation 9.5(7–14) (5995 participants). Ketoprofen 6.9(5.5–9.3) (2573 participants). Randomized controlled trial evidence suggests that adverse events for active topical NSAIDs are similar to placebo. Finally the gaps in knowledge are considered with suggestions on how further research might help. The global pain faculty was brought together by GSK under an unrestricted educational grant. 000108502 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000108502 590__ $$a2.705$$b2021 000108502 591__ $$aMEDICINE, GENERAL & INTERNAL$$b94 / 172 = 0.547$$c2021$$dQ3$$eT2 000108502 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b107 / 140 = 0.764$$c2021$$dQ4$$eT3 000108502 594__ $$a4.0$$b2021 000108502 592__ $$a0.689$$b2021 000108502 593__ $$aMedicine (miscellaneous)$$c2021$$dQ2 000108502 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000108502 700__ $$aDargan, P. 000108502 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza 000108502 700__ $$aWiffen, P. 000108502 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000108502 773__ $$g37, 2 (2021), 287-292$$pCurr. med. res. opin.$$tCURRENT MEDICAL RESEARCH AND OPINION$$x0300-7995 000108502 8564_ $$s536221$$uhttps://zaguan.unizar.es/record/108502/files/texto_completo.pdf$$yPostprint 000108502 8564_ $$s980867$$uhttps://zaguan.unizar.es/record/108502/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000108502 909CO $$ooai:zaguan.unizar.es:108502$$particulos$$pdriver 000108502 951__ $$a2023-05-18-13:28:15 000108502 980__ $$aARTICLE